OncoMatch/Clinical Trials/NCT06498154
Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy
Is NCT06498154 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for breast cancer.
Phase II multicenter prospective study on the safety of eliminating surgery for triple negative or HER2 positive breast cancer patients with clinical response to neoadjuvant radiotherapy and neoadjuvant chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression (IHC 3+ or IHC 2+ and ISH positive)
HER2 positive ( HR negative HER2 IHC score of 3+, or 2+and ISH test positive)
Required: ESR1 negative (negative)
HR negative HER2 IHC score of 3+, or 2+and ISH test positive
Required: PR (PGR) negative (negative)
HR negative HER2 IHC score of 3+, or 2+and ISH test positive
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: any medication in this study
Has used any medication in this study within 14 days prior to enrollment
Lab requirements
Blood counts
ANC ≥ 1.5 × 10^9/L; PLT ≥ 90 × 10^9/L; Hb ≥ 90 g/L
Kidney function
BUN and Cr ≤ 1.5 × ULN
Liver function
TBIL ≤ 2.5 × ULN; ALT and AST ≤ 2.5 × ULN
Cardiac function
LVEF ≥ 50%; QTcF < 470 ms (females)
LVEF ≥ 50%; 12 lead electrocardiogram: QT interval (QTcF) corrected by Fridericia method for females<470ms; blood routine: ANC ≥ 1.5 × 109/L# PLT≥90 × 109/L# Hb≥90 g/L#Blood biochemistry: TBIL ≤ 2.5 × ULN# ALT and AST ≤ 2.5 × ULN# BUN and Cr ≤ 1.5 × ULN#
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify